Pharmacogenetics of morphine: Potential implications in sickle cell disease

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 233-236

  Darbari, Deepika S ^a,b   Minniti, Caterina P ^a,b   Rana, Sohail ^c   Van Den Anker, John ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE;

ABCB1 GENE; ANALGESIC ACTIVITY; CANCER PAIN; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME POLYMORPHISM; GENE; HUMAN; LIVER MICROSOME METABOLISM; OPRM1 GENE; PAIN; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; UGT2B7 GENE; UNSPECIFIED SIDE EFFECT;

ANEMIA, SICKLE CELL; GLUCURONIDES; HUMANS; MORPHINE; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 39749183472     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21027     Document Type: Review

References (45)

1. Graves DA, Arrigo JM, Foster TS, et al. Relationship between plasma morphine concentrations and pharmacologic effects in postoperative patients using patient-controlled analgesia. Clin Pharm 1985;4:41-47.
2. Mather LE. Opioid pharmacokinetics in relation to their effects. Anaesth Intensive Care 1987;15:15-22.
3. Waters J, Thomas V. Pain from sickle cell crisis. Nurs Times 1995;16:29-31.
4. Beyer JE. Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell disease. J Pain Symptom Manage 2000;1:63-72.
5. Gerber N, Apseloff G. Death from a morphine infusion during a sickle cell crisis. J Pediatr 1993;123:322-325.
6. Kopecky EA, Jacobson S, Joshi P, et al. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther 2004;75:140-146.
7. Lotsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006;121:1-5.
8. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997;1:1-4.
9. Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol 2002;5:569-576.
10. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990;1:12-19.
11. Hollt V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 2002;12:1-2.
12. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide, a potent antagonist of morphine analgesia. Life Sci 1990;6:579-585.
13. McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: Influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990;48:236-244.
14. Klepstad P, Borchgrevink PC, Dale O, et al. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 2003;8:679-687.
15. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: Comparison of intermittent opioid vs. continuous intravenous infusion of morphine and placebo controlled study of oxygen inhalation. Pediatr Hematol Oncol 1992;4:317-326.
16. Dampier CD, Setty BN, Logan J, et al. Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr 1995;3:461-467.
17. McRorie TI, Lynn AM, Nespeca MK, et al. The maturation of morphine clearance and metabolism. Am J Dis Child 1992;146:972-976.
18. Greene RF, Miser AW, Lester CM, et al. Cerebrospinal fluid and plasma pharmacokinetics of morphine infusions in pediatric cancer patients and rhesus monkeys. Pain 1987;30:339-348.
19. Gremse DA, Fillingim E, Hoff CJ, et al. Hepatic function as assessed by lidocaine metabolism in sickle cell disease. J Pediatr 1998;132:989-993.
20. Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med 1980;69:833-837.
21. Comer GM, Ozick LA, Sachdev RK, et al. Transfusion-related chronic liver disease in sickle cell anemia. Am J Gastroenterol 1991;86:1232-1234.
22. Schafer I, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319-324.
23. Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006;81:858-863.
24. Nagar S, Remmel RP, Hebbel RP, Zimmerman CL. Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos 2004;32:98-104.
25. Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med 1990;150:501-504.
26. Platt OS, Brambilla DJ, Ross WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
27. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996;6:410-422.
28. Holthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002;58:353-356.
29. Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004;3:223-233.
30. Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003;6:566-574.
31. Lotsch J, Skarke C, Grosch S, et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002;12:3-9.
32. Skarke C, Darimont J, Schmidt H, et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003;1:107-121.
33. Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;10:1232-1239.
34. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005;5:324-336.
35. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158-to-met genotype affects mu opioid neurotransmitter responses to a pain stressor. Science 2003;5610:1240-1243.
36. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;1-2:73-78.
37. Meineke I, Freudenthaler S, Hofmann U, et al. Pharmacokinetic modeling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002;6:592-603.
38. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996;6603:759-760.
39. Loh HH, Liu HC, Cavalli A, et al. mu Opioid receptor knockout in mice: Effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 1998;2:321-326.
40. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: An evolutionary success. EMBO J 1999;18:1723-1729.
41. Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 1999;5449:2495-2498.
42. Kraus J, Borner C, Giannini E, et al. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001;276:43901-43908.
43. Chen JF, Aloyo VJ, Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA and increases mu opioid receptors in mouse striatum. Neuroscience 1993;3:669-680.
44. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Hum Genet 1977;2:125-135.
45. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000;5:1392-1399.